tamoxifen,临床注释-2,变异和临床注释数据

tamoxifen

临床注释ID

1451285240

药物名称(英)

tamoxifen

变异单倍型

CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*9, CYP2D6*10, CYP2D6*10x2, CYP2D6*11, CYP2D6*17, CYP2D6*21, CYP2D6*36, CYP2D6*41

基因

CYP2D6

证据级别

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Efficacy

表现型类别

功效

分数

226.5625

PMID计数

计数的证据

143

表现型

乳腺肿瘤

表现型(英)

Breast Neoplasms

最新日期

2021/4/29 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/1451285240

专业人口(英)

专业人口

临床等位基因

id	等位基因	注释文本
1275	*41	The CYP2D641 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D641 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.
1274	*36	The CYP2D636 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D636 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.
1273	*21	The CYP2D621 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D621 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.
1272	*17	The CYP2D617 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D617 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.
1271	*11	The CYP2D611 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D611 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.
1270	*10x2	The CYP2D610x2 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D610x2 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.
1269	*10	The CYP2D610 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients with breast cancer and carrying the CYP2D610 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.
1268	*9	The CYP2D69 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D69 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.
1267	*7	The CYP2D67 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D67 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.
1266	*6	The CYP2D66 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D66 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.
1265	*5	The CYP2D65 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D65 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.
1264	*4	The CYP2D64 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D64 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.
1263	*3	The CYP2D63 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D63 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.
1262	*2	The CYP2D62 allele is assigned as a normal function allele by CPIC. Patients with breast cancer and carrying the CYP2D62 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased likelihood of recurrence and increased event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.
1261	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients with breast cancer and carrying the CYP2D61 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased likelihood of recurrence and increased event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.

临床证据

id	证据的ID	总结
1869	1444709154	CYP2D6 4/4 is associated with increased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/4.
1868	1444709086	CYP2D6 3 + 4 + 5 + 10 + 41 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/*1 (assigned as normal metabolizer phenotype) .
1867	1444708801	CYP2D6 3 + 4 + 5 + 6 is not associated with concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1866	1444708626	CYP2D6 4/4 + 4/5 + 10/41 + 4/41 + 1/4 + 1/5 are not associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/10 + 1/41.
1865	1444708609	CYP2D6 1/4 + 1/5 are not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1864	1444708574	CYP2D6 4/4 + 4/5 + 10/41 + 4/41 + 1/4 + 1/5 are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/10 + 1/41.
1863	1444708545	CYP2D6 4/4 + 4/5 + 10/41 + 4/41 are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1862	1444708528	CYP2D6 1/4 + 1/5 are not associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1861	1444708481	CYP2D6 4/4 + 4/5 + 10/41 + 4/41 + 1/4 + 1/5 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/10 + 1/41.
1860	1444708449	CYP2D6 4/4 + 4/5 + 10/41 + 4/41 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1859	1444708297	CYP2D6 1/4 + 1/10 + 1/5 + 1/41 + 1/3 (assigned as heterozygous normal metabolizer phenotype) are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 (assigned as normal metabolizer phenotype) .
1858	1444708269	CYP2D6 3/4 + 3/5 + 4/4 + 4/5 (assigned as poor metabolizers phenotype) are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 (assigned as normal metabolizer phenotype) .
1857	1444708249	CYP2D6 3 + 4 + 5 + 10 + 41 are not associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/*1 (assigned as normal metabolizer phenotype) .
1856	1444708216	CYP2D6 3 + 4 + 5 + 10 + 41 are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/*1 (assigned as normal metabolizer phenotype) .
1855	1444706217	CYP2D6 3/4 + 3/5 + 4/4 + 4/5 + 4/7 (assigned as poor metabolizers phenotype) are associated with increased likelihood of Breast Neoplasms when treated with tamoxifen in women.
1854	1183630906	CYP2D6 6/6 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1853	1183630900	CYP2D6 6/7 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1852	1183630894	CYP2D6 5/5 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1851	1183630858	CYP2D6 4/7 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1850	1183630852	CYP2D6 4/6 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1849	1183630846	CYP2D6 4/5 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1848	1183630840	CYP2D6 4/4 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1847	1183630834	CYP2D6 4/11 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1846	1183630822	CYP2D6 3/6 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1845	1183630816	CYP2D6 3/5 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1844	1183630771	CYP2D6 3/4 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1843	827707611	CYP2D6 *10 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.
1842	827707604	CYP2D6 *4 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.
1841	827813293	CYP2D6 4 is not associated with response to antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1.
1840	827707607	CYP2D6 *5 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.
1839	827707613	CYP2D6 *17 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.
1838	827707615	CYP2D6 *41 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.
1837	827707609	CYP2D6 *6 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.
1836	827707600	CYP2D6 *3 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.
1835	827707602	CYP2D6 *1 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.
1834	769146138	Allele T is not associated with decreased overall survival when treated with tamoxifen in people with Breast Neoplasms as compared to allele C.
1833	769146144	Genotype TT is associated with increased disease free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.
1832	769146129	Genotype TT is associated with decreased relapse free time when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.
1831	769146179	Allele T is associated with decreased event-free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotype CC.
1830	769146130	Genotype TT is associated with decreased disease free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.
1829	1449717459	CYP2D6 low activity is associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 high activity.
1828	1448821366	CYP2D6 poor metabolizer is not associated with likelihood of Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer.
1827	1448260933	CYP2D6 poor metabolizers are not associated with Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.
1826	1445556597	Genotype 10/10 (assigned as poor metabolizers phenotype) are not associated with event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes 1/1 + 1/10.
1825	1445556583	CYP2D6 poor metabolizers are not associated with decreased event-free survival or overall survival when treated with tamoxifen in women with Breast Neoplasms.
1824	1445556576	CYP2D6 poor metabolizers and intermediate metabolizers are not associated with decreased event-free survival or overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.
1823	1445556526	CYP2D6 intermediate metabolizers are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.
1822	1445556517	CYP2D6 poor metabolizers are not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.
1821	1445556502	Genotype 1/1 (assigned as normal metabolizers phenotype) are associated with increased event-free survival and overall survival when treated with tamoxifen in women with Breast Neoplasms.
1820	1445556444	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1819	1445556437	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1818	1445556423	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1817	1445556415	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1816	1445556396	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1815	1445556373	CYP2D6 normal metabolizers are not associated with increased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotype *4.
1814	1445556346	Genotype 1/1 (assigned as normal metabolizers phenotype) are not associated with increased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes 3 + 4 + 5 + 10 + *41.
1813	1445556335	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes 4 + 10.
1812	1445556295	Genotype 1/1 (assigned as normal metabolizers phenotype) are associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes 3 + 4 + 5 + 10 + *41.
1811	1445402890	CYP2D6 poor metabolizers are not associated with increased risk of Breast Neoplasms when treated with tamoxifen as compared to CYP2D6 normal metabolizers.
1810	1444935762	CYP2D6 poor metabolizers and intermediate metabolizers are not associated with decreased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.
1809	1444935131	CYP2D6 poor metabolizers are not associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.
1808	1444932970	CYP2D6 normal metabolizers are associated with increased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms.
1807	1444932944	CYP2D6 poor metabolizers are not associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.
1806	1444930785	CYP2D6 poor metabolizers are not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.
1805	1444712493	CYP2D6 normal metabolizers are not associated with event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms.
1804	1183703991	CYP2D6 poor metabolizer is associated with increased risk of Recurrence when treated with tamoxifen in people with Breast Neoplasms as compared to CYP2D6 *1 (assigned as normal metabolizer phenotype) .
1803	PA166104966	Annotation of DPWG Guideline for tamoxifen and CYP2D6
1802	PA166176068	Annotation of CPIC Guideline for tamoxifen and CYP2D6
1588	1445558282	CYP2D6 3/4 + 3/5 + 3/6 + 4/11 + 4/4 + 4/5 + 4/6 + 4/7 + 5/5 + 6/6 + 6/7 (assigned as poor metabolizers phenotype) are not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1587	1445558158	CYP2D6 3/4 + 3/5 + 3/6 + 4/11 + 4/4 + 4/5 + 4/6 + 4/7 + 5/5 + 6/6 + 6/7 (assigned as poor metabolizers phenotype) are not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1586	1445558113	CYP2D6 3/4 + 3/5 + 3/6 + 4/11 + 4/4 + 4/5 + 4/6 + 4/7 + 5/5 + 6/6 + 6/7 (assigned as poor metabolizers phenotype) are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.
1585	1445400664	CYP2D6 3 + 4 + 6 + 14 + 41 are not associated with increased risk of Hot Flashes when treated with tamoxifen in women Breast Neoplasms as compared to CYP2D6 1.
1584	1444936265	CYP2D6 4/4 + 1/4 are not associated with overall survival or progression-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1583	1444935873	CYP2D6 4 + 5 + 9 + 10 + 41 are not associated with overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1.
1582	1444935416	CYP2D6 1/4 is not associated with increased risk of Death when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1581	1444935399	CYP2D6 4/4 is associated with increased risk of Death when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1580	1444935249	CYP2D6 10/10 + 4/10 + 5/10 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1579	1444935174	CYP2D6 4 is not associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1.
1578	1444934783	CYP2D6 1/1 is not associated with increased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms.
1577	1444934738	CYP2D6 1/4 + 4/4 are associated with increased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms.
1576	1444933987	CYP2D6 1/10 + 1/41 + 10/10 + 41/41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1575	1444933959	CYP2D6 1/3 + 1/4 + 1/6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1574	1444933926	CYP2D6 3/3 + 4/4 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1573	1444933870	CYP2D6 1/1 + 1/2 + 2/2 (assigned as normal metabolizers phenotype) are not associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 5/10 + 10/14 (assigned as intermediate metabolizers phenotype) .
1572	1444933835	CYP2D6 10/10 is not associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/10.
1571	1444933385	CYP2D6 5/10 + 10/10 + 1/10 + 1/5 are not associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/2.
1570	1444933287	CYP2D6 1/3 + 1/4 + 1/5 + 41/41 + 4/4 + 4/5 + 3/4 + 3/3 + 3/5 + 4/10 + 4/41 + 5/41 + 5/5 are not associated with increased risk of Death and Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1xN/4 + 1/1xN + 1/1 + 1/41 + 1/10.
1569	1444933205	CYP2D6 1/3 + 1/4 + 1/5 + 41/41 + 4/4 + 4/5 + 3/4 + 3/3 + 3/5 + 4/10 + 4/41 + 5/41 + 5/5 are associated with increased risk of Death and Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1xN/4 + 1/1xN + 1/1 + 1/41 + 1/10.
1568	1444932743	CYP2D6 4 + 5 + 10 + 41 are associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1567	1444932674	CYP2D6 3 + 4 + 5 + 6 + 7 + 9 + 10 + 41 are associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/1xN + 1/35 + 2/2.
1566	1444932651	CYP2D6 3 + 4 + 5 + 6 + 7 + 9 + 10 + 41 are not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/1xN + 1/35 + 2/2.
1565	1444932596	CYP2D6 4/4 (assigned as poor metabolizers phenotype) are not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 (assigned as normal metabolizers phenotype) .
1564	1444932107	CYP2D6 10 is not associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/*1.
1563	1444930906	CYP2D6 4 is not associated with increased likelihood of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1.
1562	1444930760	CYP2D6 41 is not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1.
1561	1444930651	CYP2D6 4 is not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1.
1560	1444930579	CYP2D6 10/10 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/10 + 1/1.
1559	1444930567	CYP2D6 10/10 is not associated with decreased concentrations of tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1558	1444930474	CYP2D6 10/10 + 10/41 + 1/5 + 2/5 + 5/10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/2 + 2/2.
1557	1444713499	CYP2D6 10/10 is associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/10.
1556	1444713399	CYP2D6 5/10 (assigned as poor metabolizers phenotype) is associated with decreased overall survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/10 + 10/10 + 1/5 + 2/10 (assigned as intermediate metabolizers phenotype) .
1555	1444713382	CYP2D6 5/10 (assigned as poor metabolizers phenotype) is associated with decreased overall survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/2 (assigned as normal metabolizers phenotype) .
1554	1444713343	CYP2D6 5/10 (assigned as poor metabolizers phenotype) is associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/10 + 10/10 + 1/5 + 2/10 (assigned as intermediate metabolizers phenotype) .
1553	1444713311	CYP2D6 5/10 (assigned as poor metabolizers phenotype) is associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/2 (assigned as normal metabolizers phenotype) .
1552	1444713116	CYP2D6 3/4 + 3/5 + 3/6 + 4/4 + 4/5 + 4/6 + 6/7 (assigned as poor metabolizers phenotype) are associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/2 + 1/35 + 2/2 + 2/35 + 35/35 (assigned as normal metabolizers phenotype) .
1551	1444713029	CYP2D6 3/4 + 3/5 + 3/6 + 4/4 + 4/5 + 4/6 + 6/7 (assigned as poor metabolizers phenotype) are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/2 + 1/35 + 2/2 + 2/35 + 35/35 + 1/1xN + 2/1xN + 1/2xN.
1550	1444712986	CYP2D6 1/4 is not associated with decreased event-free survival, overall survival and Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1549	1444712957	CYP2D6 4/4 is associated with decreased event-free survival and Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1548	1444712932	CYP2D6 4/4 + 1/4 are not associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1547	1444712890	CYP2D6 4/4 + 1/4 are associated with decreased event-free survival and Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1546	1444712685	CYP2D6 10/10 is not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1545	1444712664	CYP2D6 1/1 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/10.
1544	1444712651	CYP2D6 10/10 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/10.
1543	1444712614	CYP2D6 10/10 is not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/10.
1542	1444712582	CYP2D6 4/4 + 3/4 + 4/10 + 10/10 are not associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/2 + 1/1xN.
1541	1444712505	CYP2D6 1/4 + 1/10 + 4/10 + 10/10 + 4/4 are not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1540	1444712361	CYP2D6 3/4 + 4/4 + 4/6 + 6/6 + 1/4 + 1/41 + 4/41 + 1/3 + 4/10 + 3/41 + 1/6 + 1/10 + 10/10 + 10/41 + 6/41 are not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1539	1444712315	CYP2D6 4/4 is associated with increased likelihood of Breast Neoplasms when treated with tamoxifen in women.
1538	1444711687	CYP2D6 10/10 is associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms.
1537	1444711651	CYP2D6 10/5 + 10/10 + 10/41 are associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/2 + 1/5 + 1/10 + 1/36 + 1/41 + 2/2 + 2/4 + 2/10 + 10/35.
1536	1444711617	CYP2D6 10/5 + 10/10 + 10/41 are not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/2 + 1/5 + 1/10 + 1/36 + 1/41 + 2/2 + 2/4 + 2/10 + 10/35.
1535	1444711544	CYP2D6 10/10 + 10/41 + 5/10 + 5/5 are not associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/10 + 1/41 + 1/5.
1534	1444711494	CYP2D6 10/10 + 10/41 + 5/10 + 5/5 are not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/10 + 1/41 + 1/5.
1533	1444711469	CYP2D6 1/10 + 1/41 + 1/5 + 10/10 + 10/41 + 5/10 + 5/5 are not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1532	1444710956	CYP2D6 1/4 + 1/5 + 1/10 + 1/10x2 + 1/36 + 1/41 + 5/5 + 5/10 + 5/21 + 10/10 + 10/21 + 21/41 are not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/1xN.
1531	1444710646	CYP2D6 10/10 is not associated with overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.
1530	1444710610	CYP2D6 10/10 is not associated with event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.
1529	1444710359	CYP2D6 3/4 + 4/4 + 4/5 are not associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/3 + 1/4 + 1/41 + 41/41.
1528	1444710323	CYP2D6 3/4 + 4/4 + 4/5 are not associated with decreased overall survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/3 + 1/4 + 1/41 + 41/41.
1527	1444710290	CYP2D6 3/4 + 4/4 + 4/5 are associated with decreased overall survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/3 + 1/4 + 1/41 + 41/41.
1526	1444710214	CYP2D6 3 + 4 + 5 + 6 + 10 + 41 are not associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1525	1444709919	CYP2D6 4/4 + 4/41 + 1/5 + 2/5 are associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in people with Breast Neoplasms as compared to CYP2D6 3/4 + 4/9 + 9/10 + 9/41 + 41/41 + 1/4 + 1/6 + 2/4 + 2/20 + 35/4 + 1/10 + 1/9 + 1/41 + 35/10 + 2/9 + 2/41 + 35/41 + 35/9 + 1/1 + 2/2 + 1/2 + 1/35 + 1xN/2.
1524	1444709809	CYP2D6 4 + 3 + 5 + 10 + 41 are not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in people with Breast Neoplasms as compared to CYP2D6 1 + 2 + 35.
1523	1444709772	CYP2D6 10/10 is associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/10.
1522	1444709657	CYP2D6 4/4 + 4/5 + 4/10 are associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/2 + 1/10 + 1/4.
1521	1444709600	CYP2D6 4 + 5 + 10 + 14 + 21 + 36 + 41 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/*1.
1520	1444709474	CYP2D6 1/4 + 1/5 + 1/10 + 1/10x2 + 10/10x2 + 1/14 + 1/21 + 1/36 + 1/41 + 1xN/10 + 5/5 + 5/10 + 5/21 + 5/41 + 10/10 + 10/21 + 10/36 + 10/41 are associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1.
1519	1444709457	CYP2D6 4/4 is associated with decreased risk of Hot Flashes when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/4 + 1/1.
1518	1444709440	CYP2D6 4/4 is not associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/4 + 1/1.
1517	1444709414	CYP2D6 4/4 is associated with decreased event-free survival and Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/4 + 1/1.
1516	1444709399	CYP2D6 4/4 is associated with decreased progression-free survival when treated with anthracyclines and related substances and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/4.
1515	1444709377	CYP2D6 4/4 is not associated with decreased progression-free survival when treated with anthracyclines and related substances and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/1 + 1/4.
1514	1444709176	CYP2D6 4 is not associated with increased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 1/*1.

临床病史

id	类型	评论
1398	Update	Added DPWG guideline as evidence and added sentence regarding no recommendation for UMs.
1397	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1396	Update	Level 1A because of CPIC guideline.
1395	Create	Combined VAs for tamoxifen and VAs for "antineoplastic agents and tamoxifen"

最新招商产品更多>>